Fears Of Too Many OTC Choices Should Not Restrict Switches, Stakeholders Say
This article was originally published in The Tan Sheet
Executive Summary
FDA and its advisory committees should not meddle with the free market by potentially limiting Rx-to-OTC switches based on how crowded a self-care category is or by removing “obsolete” ingredients from the market once new, improved treatments become available, stakeholders argue.